IL1B and B-cell chronic lymphocytic leukemia: In contrast, ibrutinib treatment of the CLL cybrid caused a significant decrease in the mean-difference fold change of IL1β (p < 0.0001), whereas it had no significant effect on the expression of other inflammatory genes (Figure 4).